Indirect comparison of intravenous vs. subcutaneous C1-inhibitor placebo-controlled trials for routine prevention of hereditary angioedema attacks

INTRODUCTION: For prophylaxis of hereditary angioedema (HAE) attacks, replacement therapy with human C1-inhibitor (C1-INH) treatment is approved and available as intravenous [C1-INH(IV)] (Cinryze(®)) and subcutaneous [C1-INH(SC)] HAEGARDA(®) preparations. In the absence of a head-to-head comparative...

Descripción completa

Detalles Bibliográficos
Autores principales: Bernstein, Jonathan A., Li, Huamin Henry, Craig, Timothy J., Manning, Michael E., Lawo, John-Philip, Machnig, Thomas, Krishnarajah, Girishanthy, Fridman, Moshe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407188/
https://www.ncbi.nlm.nih.gov/pubmed/30899278
http://dx.doi.org/10.1186/s13223-019-0328-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407188/
https://www.ncbi.nlm.nih.gov/pubmed/30899278
http://dx.doi.org/10.1186/s13223-019-0328-3

Ejemplares similares